Form 8-K Intellia Therapeutics, For: Nov 07
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Wall St rises as oil slide offers respite after Fed rate hike
- Oil falls 2% to one-week low as Middle East supply disruption fears ease
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- RBC bullish on Kraft Heinz, sees return to growth in 2027
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Paradium AI (PAAI) Halted, News Pending
Stifel Reiterates Buy Rating on Intellia Therapeutics (NTLA)
November 7, 2024 10:43 AM ESTStifel analyst Dae Gon Ha reiterated a Buy rating and $54.00 price target on Intellia Therapeutics (NASDAQ: NTLA).
The analyst comments "NTLA has one of the most expansive and diversified pipelines within the CRISPR/Cas gene editing field, and with 3 Ph.3 studies... More
